- Home
- TENB vs ARQT Comparison
TENB vs ARQT Comparison
Compare TENB & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TENB | ARQT |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TENB | ARQT |
|---|---|---|
| Price | $27.79 | $21.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 6 |
| Target Price | $31.69 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 3.7M | 2.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.23 | ★ 88.79 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $999,405,000.00 | $376,072,000.00 |
| Revenue This Year | $9.37 | $34.85 |
| Revenue Next Year | $7.04 | $29.39 |
| P/E Ratio | $2,929.00 | ★ N/A |
| Revenue Growth | 11.04 | ★ 91.34 |
| 52 Week Low | $15.73 | $12.72 |
| 52 Week High | $35.69 | $31.77 |
Technical Indicators
Market Signals| Indicator | TENB | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 61.29 | 48.26 |
| Support Level | $25.69 | $21.12 |
| Resistance Level | $30.79 | $21.95 |
| Average True Range (ATR) | 1.72 | 0.83 |
| MACD | 0.28 | 0.17 |
| Stochastic Oscillator | 65.93 | 73.40 |
Price Performance
Historical ComparisonAbout TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.